异动解读 | 花旗高盛看好未来两年催化剂再鼎医药盘中大涨5%

异动解读2025-03-04

再鼎医药(ZLAB)今日盘中大涨5%,主要受多家投行看好该股未来发展前景所推动。

中金发布研报称,维持再鼎医药"跑赢大市"评级,并将目标价上调22.5%至34.41港元。该行认为,再鼎医药去年业绩优于预期,主要受益于核心产品艾加莫德(Efgartigimod)收入高企。公司给出今年收入指引为5.6亿至5.9亿美元,第四季度实现盈利持平。中金期待再鼎医药今明两年将有大量催化剂,包括有望在今年上半年就ZL-1310和Bemarituzumab分别公布数据和递交上市申请,明年也将看到KarXT商业化进程。

花旗将再鼎医药目标价轻微上调至71美元,给予"买入"评级。该行认为,今年渠道数据、Vygart的增长,以及2026年KarXT获准上市的前景,将重新激发投资者对该股的热情。高盛也将再鼎医药目标价上调至42.01港元,重申2025年是该公司的发展里程碑年。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1168191430?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-04 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168191430","market":"us","top_or_hot":-1,"title":"异动解读 | 花旗高盛看好未来两年催化剂 再鼎医药盘中大涨5%","media":"异动解读","content":"<p>再鼎医药(ZLAB)今日盘中大涨5%,主要受多家投行看好该股未来发展前景所推动。</p>\n\n<p>中金发布研报称,维持再鼎医药\"跑赢大市\"评级,并将目标价上调22.5%至34.41港元。该行认为,再鼎医药去年业绩优于预期,主要受益于核心产品艾加莫德(Efgartigimod)收入高企。公司给出今年收入指引为5.6亿至5.9亿美元,第四季度实现盈利持平。中金期待再鼎医药今明两年将有大量催化剂,包括有望在今年上半年就ZL-1310和Bemarituzumab分别公布数据和递交上市申请,明年也将看到KarXT商业化进程。</p>\n\n<p>花旗将再鼎医药目标价轻微上调至71美元,给予\"买入\"评级。该行认为,今年渠道数据、Vygart的增长,以及2026年KarXT获准上市的前景,将重新激发投资者对该股的热情。高盛也将再鼎医药目标价上调至42.01港元,重申2025年是该公司的发展里程碑年。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 花旗高盛看好未来两年催化剂 再鼎医药盘中大涨5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 花旗高盛看好未来两年催化剂 再鼎医药盘中大涨5%\n</h2>\n\n<h4 class=\"meta\">\n\n2025-03-04 22:40 北京时间&nbsp;&nbsp;&nbsp;<strong>异动解读</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>再鼎医药(ZLAB)今日盘中大涨5%,主要受多家投行看好该股未来发展前景所推动。\n中金发布研报称,维持再鼎医药\"跑赢大市\"评级,并将目标价上调22.5%至34.41港元。该行认为,再鼎医药去年业绩优于预期,主要受益于核心产品艾加莫德(Efgartigimod)收入高企。公司给出今年收入指引为5.6亿至5.9亿美元,第四季度实现盈利持平。中金期待再鼎医药今明两年将有大量催化剂,包括有望在今年上半年就...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZLAB","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1168191430","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168191430","pubTimestamp":1741099241,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"再鼎医药今日盘中大涨5%,主要受多家投行看好该股未来发展前景所推动。中金发布研报称,维持再鼎医药\"跑赢大市\"评级,并将目标价上调22.5%至34.41港元。花旗将再鼎医药目标价轻微上调至71美元,给予\"买入\"评级。该行认为,今年渠道数据、Vygart的增长,以及2026年KarXT获准上市的前景,将重新激发投资者对该股的热情。高盛也将再鼎医药目标价上调至42.01港元,重申2025年是该公司的发展里程碑年。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ZLAB":"再鼎医药"},"translate_title":"Interpretation of changes: Citigroup and Goldman Sachs are optimistic about catalysts in the next two years, Zai Lab rose 5% during the session","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZLAB":1},"content_text":"再鼎医药(ZLAB)今日盘中大涨5%,主要受多家投行看好该股未来发展前景所推动。\n中金发布研报称,维持再鼎医药\"跑赢大市\"评级,并将目标价上调22.5%至34.41港元。该行认为,再鼎医药去年业绩优于预期,主要受益于核心产品艾加莫德(Efgartigimod)收入高企。公司给出今年收入指引为5.6亿至5.9亿美元,第四季度实现盈利持平。中金期待再鼎医药今明两年将有大量催化剂,包括有望在今年上半年就ZL-1310和Bemarituzumab分别公布数据和递交上市申请,明年也将看到KarXT商业化进程。\n花旗将再鼎医药目标价轻微上调至71美元,给予\"买入\"评级。该行认为,今年渠道数据、Vygart的增长,以及2026年KarXT获准上市的前景,将重新激发投资者对该股的热情。高盛也将再鼎医药目标价上调至42.01港元,重申2025年是该公司的发展里程碑年。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168191430","isCrawlerRequest":true}

异动解读 | 花旗高盛看好未来两年催化剂 再鼎医药盘中大涨5%

精彩评论

异动解读 | 花旗高盛看好未来两年催化剂再鼎医药盘中大涨5%